Detection and Treatment of Children and Adolescents with Dyslipidemia

Kwiterovich, Peter O.

doi:10.1007/978-1-60761-424-1_5

Cited by 1 publication

(1 citation statement)

References 152 publications

(264 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Причем наиболее значимым был результат одного из первых исследований статинов -4S, в котором было выявлено 42%-ное снижение риска СС-собы тий у больных СД 2-го типа, которые принимали симвастатин в дозе от 20 до 40 мг, по сравнению с лицами, получавшими плацебо (p < 0,001). В дальнейшем исследование HPS подтвердило высокую эффективность симвастатина для снижения риска СС-событий как для первичной, так и для вторичной профилактики (на 27 и 26% соответственно) [11].…”

Section: пациенты с сахарным диабетом 2го типа  пациенты очень высоunclassified

The specific treatment of dyslipidemia in patients with diabetes type 2

Уразгильдеева¹,

Малыгина²

2016

Med. sov.

View full text Add to dashboard Cite

Section: пациенты с сахарным диабетом 2го типа  пациенты очень высоunclassified

The specific treatment of dyslipidemia in patients with diabetes type 2

Уразгильдеева¹,

Малыгина²

2016

Med. sov.

View full text Add to dashboard Cite

Case Studies in Pediatric Lipid Disorders and Their Management

Ashraf

Sunil

Bamba³

et al. 2021

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Identification of modifiable risk factors, including genetic and acquired disorders of lipid and lipoprotein metabolism is increasingly recognized as an opportunity to prevent premature cardiovascular disease (CVD) in at-risk youth. Pediatric endocrinologists are at the forefront of this emerging public health concern and can be instrumental in beginning early interventions to prevent premature CVD-related events during adulthood. Aim In this article, we use informative case presentations to provide practical approaches to the management of pediatric dyslipidemia. Cases We present three scenarios which are commonly encountered in clinical practice: isolated elevation of low-density lipoprotein cholesterol (LDL-C), combined dyslipidemia, and severe hypertriglyceridemia. Treatment with statin is indicated when the LDL-C is ≥190 mg/dL (4.9 mmol/L) in children ≥10 years of age. For LDL-C levels between 130-189 mg/dL (3.4 – 4.89 mmol/L) despite dietary and lifestyle changes, the presence of additional risk factors and comorbid conditions would favor statin therapy. In the case of combined dyslipidemia, the primary treatment target is LDL-C ≤130 mg/dL (3.4 mmol/L) and the secondary target non-HDL-C <145 mg/dL(3.7 mmol/L). If the triglyceride is ≥400 mg/dL (4.5 mmol/L), prescription omega-3 fatty acids and fibrates are considered. In the case of triglyceride >1000 mg/dL (11.3mmol/L), dietary fat restriction remains the corner stone of therapy, even though the landscape of medications is changing. Conclusion Gene variants, acquired conditions or both are responsible for dyslipidemia during childhood. Extreme elevations of triglycerides can lead to pancreatitis. Early identification and management of dyslipidemia and cardiovascular risk factors is extremely important.

show abstract

Detection and Treatment of Children and Adolescents with Dyslipidemia

Cited by 1 publication

References 152 publications

The specific treatment of dyslipidemia in patients with diabetes type 2

The specific treatment of dyslipidemia in patients with diabetes type 2

Case Studies in Pediatric Lipid Disorders and Their Management

Contact Info

Product

Resources

About